ArticleThe EMBO journal2009
Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex.
Article in The EMBO journal, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 71 citations in OpenAlex.
- Mapping of C5-Blocking Monoclonal Antibodies Reveals New C5 Inhibitory Epitopes and Novel Modes of C5 Inhibition.Immunology · 2026Article
- Complement C3 recognition by C3 convertases.Science advances · 2026Article
- Structural insights into C3 convertase activity of the classical pathway of complement.Nature communications · 2025Article
- Factor B as a therapeutic target for the treatment of complement-mediated diseases.Frontiers in immunology · 2025Review
- Immunity and Coagulation in COVID-19.International journal of molecular sciences · 2024Review
- Article
- Refining the domain architecture model of the replication origin firing factor Treslin/TICRR.Life science alliance · 2022Article
- Complement Factor B Mediates Ocular Angiogenesis through Regulating the VEGF Signaling Pathway.International journal of molecular sciences · 2021Article
- Combination of a Novel Genetic Variant inFrontiers in genetics · 2021Article
- Animal toxins - Nature's evolutionary-refined toolkit for basic research and drug discovery.Biochemical pharmacology · 2020Review
- Review
- How novel structures inform understanding of complement function.Seminars in immunopathology · 2018Review
- Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses.Nature structural & molecular biology · 2017Article
- Identification of C3b-Binding Small-Molecule Complement Inhibitors Using Cheminformatics.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense.Immunological reviews · 2016Review
- Solution Structures of Complement C2 and Its C4 Complexes Propose Pathway-specific Mechanisms for Control and Activation of the Complement Proconvertases.The Journal of biological chemistry · 2016Article
- Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode.The EMBO journal · 2016Article
- Structural basis for therapeutic inhibition of complement C5.Nature structural & molecular biology · 2016Article
- Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.The Journal of biological chemistry · 2016Article
- Complement System Part I - Molecular Mechanisms of Activation and Regulation.Frontiers in immunology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune protection by the complement system critically depends on assembly of C3 convertases on the surface of pathogens and altered host cells. These short-lived protease complexes are formed through pro-convertases, which for the alternative pathway consist of the complement component C3b and the pro-enzyme factor B (FB). Here, we present the crystal structure at 2.2-A resolution, small-angle X-ray scattering and electron microscopy (EM) data of the pro-convertase formed by human FB and cobra venom factor (CVF), a potent homologue of C3b that generates more stable convertases. FB is loaded onto CVF through its pro-peptide Ba segment by specific contacts, which explain the specificity for the homologous C3b over the native C3 and inactive products iC3b and C3c. The protease segment Bb binds the carboxy terminus of CVF through the metal-ion dependent adhesion site of the Von Willebrand factor A-type domain. A possible dynamic equilibrium between a 'loading' and 'activation' state of the pro-convertase may explain the observed difference between the crystal structure of CVFB and the EM structure of C3bB. These insights into formation of convertases provide a basis for further development of complement therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.